research use only
Cat.No.S8441
| Related Targets | EGFR VEGFR JAK PDGFR FGFR Src FLT FLT3 HER2 Bcr-Abl |
|---|---|
| Other HIF Inhibitors | PT2399 PX-478 Dihydrochloride BAY 87-2243 KC7F2 Lificiguat (YC-1) IOX2 Molidustat (BAY 85-3934) PT2385 IDF-11774 MK-8617 |
| Cell Lines | Assay Type | Concentration | Incubation Time | Formulation | Activity Description | PMID |
|---|---|---|---|---|---|---|
| AGS | Function assay | Inhibition of hypoxia induced HIF1 transcriptional activity in human AGS cells by cell-based HRE reporter assay, IC50=0.7μM | 17328532 | |||
| Hep3B | Function assay | Inhibition of hypoxia induced HIF1 transcriptional activity in human Hep3B cells by cell-based HRE reporter assay, IC50=2.6μM | 17328532 | |||
| Hep3B | Function assay | 10 uM | Suppression of hypoxia-induced VEGF mRNA expression in human Hep3B cells at 10 uM | 17328532 | ||
| Hep3B | Function assay | 10 uM | Suppression of hypoxia-induced EPO mRNA expression in human Hep3B cells at 10 uM | 17328532 | ||
| HCT116 | Function assay | 16 hrs | Inhibition of HIF1alpha in human HCT116 cells under hypoxic condition after 16 hrs by dual luciferase reporter gene assay, IC50=2.44μM | 23153200 | ||
| HeLa | Function assay | 12 hrs | Inhibition of hypoxia-induced HIF1alpha transcriptional activity in human HeLa cells expressing HRE-Luc after 12 hrs by luciferase reporter gene assay, IC50=21μM | 24900662 | ||
| HeLa | Function assay | 30 uM | 4 hrs | Inhibition of hypoxia-induced HIF1alpha nuclear translocation in human HeLa cells at 30 uM after 4 hrs by immunofluorescence analysis | 24900662 | |
| HeLa | Function assay | 30 uM | 4 hrs | Inhibition of hypoxia-induced HIF1alpha accumulation in human HeLa cells at 30 uM after 4 hrs by Western blot analysis | 24900662 | |
| HCT116 | Function assay | 12 hrs | Inhibition of HIF-1alpha in human HCT116 cells incubated for 12 hrs under hypoxic conditions by Western blotting and HRE-luciferase reporter assay, IC50=4.4μM | 25356789 | ||
| HCT116 | Function assay | 10 uM | Reduction in ATP production in human HCT116 cells at 10 uM by luciferase based assay | 25356789 | ||
| HCT116 | Function assay | 10 uM | Inhibition of MDH2 in human HCT116 cells assessed as AMPK activation at 10 uM by immunoblot assay | 25356789 | ||
| HCT116 | Function assay | 10 uM | Inhibition of MDH2 in human HCT116 cells assessed as reduction in ACC phosphorylation at 10 uM by immunoblot assay | 25356789 | ||
| HCCLM3 | Function assay | Inhibition of HIF1alpha transcriptional activity in hypoxia-induced human HCCLM3 cells co-transfected with luciferase reporter plasmid containing five copies of HREs and pRL-SV40 plasmid encoding Renilla luciferase incubated with compound under normoxia f, IC50=3.08μM | 31556611 | |||
| HCCLM3 | Function assay | 10 uM | 1 hr | Inhibition of HIF1alpha accumulation in hypoxia-induced human HCCLM3 cells at 10 uM incubated with compound under normoxia for 1 hr followed by hypoxia induction and measured after 24 hrs by Western blot analysis | 31556611 | |
| Click to View More Cell Line Experimental Data | ||||||
|
In vitro |
DMSO
: 24 mg/mL
(55.1 mM)
Water : Insoluble Ethanol : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 435.51 | Formula | C26H29NO5 |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 934593-90-5 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | AC1-001 | Smiles | COC(=O)C1=CC(=C(C=C1)O)NC(=O)COC2=CC=C(C=C2)C34CC5CC(C3)CC(C5)C4 | ||
| Targets/IC50/Ki |
BCRP
HIF
(Cell-free assay) 4.4 μM
MDH2
(Cell-free assay) 6.3 μM
|
|---|---|
| In vitro |
LW6 inhibits HIF-1α expression induced by hypoxia. It promotes apoptosis preferentially in hypoxic cells. Treatment with LW6 presents no additive effect on cell cycle arrest. LW6 induces ROS formation through the depolarization of MMP in hypoxic cells. Although LW6 increases mitochondrial ROS production, the combination with hypoxia induces a marked increase in ROS production and this high level is maintained up until 24 h. LW6 is also a specific inhibitor of MDH2. As MDH2 is known to serve a significant role in the citric acid cycle at the mitochondrial membrane, LW6 indirectly reduces the activity of the mitochondrial respiratory chain through the inhibition of MDH2.In contrast to BCRP, LW6 has no inhibition effect on the functional activity and gene expression of P-gp. LW6 also down-regulates BCRP expression at concentrations of 0.1-10 μM. Furthermore, cells become more susceptible to the cytotoxicity of anticancer drugs in the presence of LW6. |
| In vivo |
LW6 exerts marked anti-tumor efficacy in vivo and causes reductions in HIF-1α expression levels in mice carrying xeno-grafts of HCT116 cells. LW6 improves the cytotoxicity and bioavailability of anticancer drugs translocated by BCRP. |
References |
|
| Methods | Biomarkers | Images | PMID |
|---|---|---|---|
| Western blot | HIF-1α E-cadherin / PIMT |
|
26017562 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.